COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

Title:

COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

Document Type and Number:

WIPO Patent Application WO/2022/245089

Kind Code:

A1

Abstract:

The present invention relates to a composition for treatment of COVID-19, comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, the use of a pharmaceutically acceptable salt of TDCA was found to have an effect of treating clinical symptoms caused by a SARS-CoV-2 infection and early full recovery through alleviating inflammation and suppressing inflammatory cytokines. Thus, TDCA or a pharmaceutically acceptable salt thereof may be used as an active ingredient of a composition for preventing or treating lower respiratory tract infections including COVID-19.

More Like This:

WO/2012/017369	A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING BIOPOLYMER, BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE AND A PROCESS TO MAKE IT
JP6615912	Anti-cancer adjuvant containing panaxadiol ginsenoside compounds
WO/2015/036442	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION

Inventors:

SEONG SEUNG YONG (KR)
HAN SEON AE (KR)

Application Number:

PCT/KR2022/007007

Publication Date:

November 24, 2022

Filing Date:

May 17, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SHAPERON INC (KR)

International Classes:

A61K31/575; A61P29/00; A61P31/14

Foreign References:

KR20130103469A	2013-09-23
US20180282704A1	2018-10-04

Other References:

MÜHLBAUER, M. ET AL.: "Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-κB signal transduction and IL-8 gene expression in colonic epithelial cells.", AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY., vol. 286, no. 6, 2004, pages G1000 - G1008, XP055804674
LI, N. ET AL.: "Tauroursodeoxycholic acid (TUDCA) inhibits influenza A viral infection by disrupting viral proton channel M2. Science bulletin", vol. 64, 2019, pages 180 - 188, XP055798901
YANGUAS‐CASÁS, N. ET AL.: "TUDCA: An agonist of the bile acid receptor GPBAR1/TGR5 with anti‐inflammatory effects in microglial cells", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 232, 2017, pages 2231 - 2245, XP055594150
FAJGENBAUM, N ENGL J MED., vol. 383, no. 23, 3 December 2020 (2020-12-03), pages 2255 - 2273

Attorney, Agent or Firm:

KIM, Bo Jung (KR)

Download PDF:

View/Download PDF PDF Help

Previous Patent: SURGICAL TOOL DEVICE HAVING WIRE HYSTERESIS COMPENSATION FUNCTION AND METHOD FOR CONTROLLING SAME

Next Patent: ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME